Caldwell Sutter Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Caldwell Sutter Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-160	Closed	-$4.81K	–	903
2025 Q3	$4.81K	Buy	160 +37	+30%	+$1.11K	﹤0.01%	637
2025 Q2	$4.47K	Hold	123	–	–	﹤0.01%	627
2025 Q1	$4.45K	Hold	123	–	–	﹤0.01%	640
2024 Q4	$5.17K	Hold	123	–	–	﹤0.01%	635
2024 Q3	$6.83K	Hold	123	–	–	﹤0.01%	604
2024 Q2	$5.05K	Hold	123	–	–	﹤0.01%	632
2024 Q1	$5.74K	Hold	123	–	–	﹤0.01%	615
2023 Q4	$5.88K	Hold	123	–	–	﹤0.01%	606
2023 Q3	$4.38K	Hold	123	–	–	﹤0.01%	617
2023 Q2	$5.67K	Buy	+123	New	+$5.71K	﹤0.01%	592

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Caldwell Sutter Capital's RARE Position: Q4 2025 in Review

Caldwell Sutter Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 160 shares — an estimated $4.81K sold.

Caldwell Sutter Capital first reported a position in RARE in Q2 2023 and held it in 10 quarters. The position peaked at $6.83K in Q3 2024. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Caldwell Sutter Capital reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Caldwell Sutter Capital sold 160 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $4.81K.
Caldwell Sutter Capital first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and held it in 10 quarters.
Caldwell Sutter Capital's Ultragenyx Pharmaceutical position peaked at $6.83K in Q3 2024.
288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Caldwell Sutter Capital's 13F filing for Q4 2025, filed 30 Jan 2026.